Skip to main content
SpringerLink
Log in

Neoadjuvant hormone therapy before radical prostatectomy does not improve disease-specific survival

  • Clinical Trials Review
  • Published:
Current Urology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Steiner MS: Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol 1995, 153:1085–1096.

    Article  PubMed  CAS  Google Scholar 

  2. Fair WR, Aprikian AG, Cohen D, et al.: Use of neoadjuvant androgen deprivation therapy in clinical localized prostate cancer. Clin Invest Med 1993, 16:516–522.

    PubMed  CAS  Google Scholar 

  3. Gleave ME, Goldenberg L, Jones EC, et al.: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996, 155:213–219.

    Article  PubMed  CAS  Google Scholar 

  4. Labrie F, Cusan L, Gomez JL, et al.: Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994, 44:29–37.

    Article  Google Scholar 

  5. Pilepich MV, Krall JM, al-Sarraf M, et al.: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995, 45:616–623.

    Article  PubMed  CAS  Google Scholar 

  6. Soloway MS, Sharifi R, Wajsman Z, et al.: Lupron Depot Neoadjuvant Prostate Study Group: randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM) prostate cancer. J Urol 1995, 154:424–428.

    Article  PubMed  CAS  Google Scholar 

  7. Civantos F, Sadek S, Obek C, et al.: Neoadjuvant hormonal therapy prior to radical prostatectomy. Mol Urol 1999, 3:201–204.

    Google Scholar 

  8. Fair WR, Rabbani F, Bastar A, Betancourt J: Neoadjuvant hormone therapy before radical prostatectomy: update on the Memorial Sloan-Kettering Cancer Center Trials. Mol Urol 1999, 3:253–260.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Tennessee, Memphis, 956 Court Avenue, Room H216, 38163, Memphis, TN, USA

    Mitchell S. Steiner MD

Authors
  1. Mitchell S. Steiner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steiner, M.S. Neoadjuvant hormone therapy before radical prostatectomy does not improve disease-specific survival. Curr Urol Rep 1, 7–8 (2000). https://doi.org/10.1007/s11934-000-0028-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-000-0028-y

Keywords

Search

Navigation